Search

Recent epidemiological studies suggest that chronic pain is a clinically under-recognised cause for cardiovascular morbidity and mortality. Up to 30% of patients undergoing surgery report chronic pain, but the impact of pre-existing pain on postoperative cardiovascular outcomes is not known. Chronic pain and cardiovascular dysfunction share fundamental pathological mechanisms. Chronic pain is a modifiable risk factor for perioperative cardiovascular morbidity. [ABSTRACT FROM AUTHOR]

In the pathogenesis of heart disease, oxidative stresses, inflammations, and vascular dysfunction are interconnected components. The goal of the current investigation was to determine how naringin could reduce oxidative stress, inflammation, and vascular dysfunction in rats that received LPS. Lipopolysaccharide (LPS) was injected into a rat's tail vein once a week for 6 weeks in order to establish chronic vascular inflammation and oxidative stress. Endothelial activity was considerably reduced in LPS group animals compared to normal control, as well as endothelial performances were dependently improved by naringin therapy. Nevertheless, there was an augmentation in aortic superoxide dismutase (SOD) function, nitric oxide (NO) concentration, and constitutive nitric oxide synthase (cNOS) activity, while reduction in aortic malondialdehyde (MDA) levels and inducible nitric oxide synthase (iNOS) activity. These findings suggest that long-term naringin therapy may help to avoid cardiovascular challenges posed by endothelial dysfunction. [ABSTRACT FROM AUTHOR]

Background: The inadequate inclusion of sex and gender in medical research has resulted in biased clinical guidance and disparities in knowledge and patient outcomes. Despite efforts by regulatory and funding agencies, opportunities to generate sex-specific knowledge are frequently overlooked. While certain disciplines in cardiovascular medicine have made notable progress, these advances have yet to permeate the literature on perioperative cardiovascular complications in non-cardiac surgery. Prompted by the recent findings on sex-specific perioperative cardiovascular outcomes, this review aims to scope the literature in this field and categorize methodological approaches used to incorporate sex and gender in studies of this patient population. Methods: Joanna Briggs Institute (JBI) methodology for scoping reviews will be followed in stages elaborated by Levac (2010). A comprehensive search strategy will be used to identify relevant primary research published since 2010. Screening will be performed by independent reviewers using predefined inclusion and exclusion criteria. Data will be extracted from full text and supplementary materials of selected articles. Results will be presented as proportions of studies reporting sex and gender, the assigned purpose of these variables in analysis, and where they are reported in the article. In addition, articles will be mapped to the source, country of origin, and year of publication. Narrative summaries will be provided to outline key findings and assess the depth of the literature within each of the major topics (risk assessment/prediction, diagnosis, treatment, prognosis, and outcomes). Discussion: Increasing recognition of the profound and complex implications of sex and gender in medicine has fuelled calls for greater attention to participation equity, sex-specific analysis and reporting. Focusing on perioperative cardiovascular complications, this review has the potential to identify knowledge gaps for future research, as well as areas of strength that could support formal knowledge synthesis or secondary analysis of data from past research. Scoping review registration: Submitted on August 15th, 2023 (Web of Science osf.io/u25sf) [ABSTRACT FROM AUTHOR]

Diabetes mellitus is a chronic disease characterized by metabolic defects, including insulin deficiency and resistance. Individuals with diabetes are at increased risk of developing cardiovascular complications, such as atherosclerosis, coronary artery disease, and hypertension. Conventional treatment methods, though effective, are often challenging, costly, and may lead to systemic side effects. This study explores the potential of nanomedicine applications, specifically Metal–Organic Frameworks (MOFs), as drug carriers to overcome these limitations. The Materials Institute Lavoisier-89 nanoparticles (nanoMIL-89) have previously demonstrated promise as a drug delivery vehicle for chronic diseases due to their anti-oxidant and cardio-protective properties. In this investigation, nanoMIL-89 was loaded with the anti-diabetic drug metformin (MET), creating MET@nanoMIL-89 formulation. We examined the drug release kinetics of MET@nanoMIL-89 over 96 h and assessed its impact on the viability of various endothelial cells. Furthermore, we investigated the nanoformulation effect on the inflammatory marker CXCL8 in these cells and explored its influence on phosphorylated eNOS, total eNOS, and AKT levels. Our findings indicate that nanoMIL-89 effectively released metformin over 96 h and caused a concentration-dependent reduction in CXCL8 release from endothelial cells. Notably, MET@nanoMIL-89 reduced dihydroethidium levels and increased phosphorylated eNOS, total eNOS, and AKT levels. Our results underscore the potential of nanoMIL-89 as a versatile potential drug delivery platform for anti-diabetic drugs, offering a prospective therapeutic approach for diabetic patients with associated cardiovascular complications. [ABSTRACT FROM AUTHOR]

Neurological disorders encompass a complex and heterogeneous spectrum of diseases affecting the brain, spinal cord, and peripheral nervous system, each presenting unique challenges that extend well beyond primary neurological symptoms. These disorders profoundly impact cardiovascular health, prompting an intensified exploration into the intricate interconnections between the neurological and cardiovascular systems. This review synthesizes current insights and research on cardiovascular comorbidities associated with major neurological conditions, including stroke, epilepsy, Parkinson's disease, multiple sclerosis, and Alzheimer's disease. The cardiovascular sequelae of these neurological disorders are multifactorial. For instance, strokes not only predispose individuals to arrhythmia and heart failure but also exacerbate preexisting cardiovascular risk factors. Similarly, epilepsy is associated with autonomic dysregulation and an elevated risk of sudden cardiac death, underscoring the necessity for vigilant cardiac monitoring in affected individuals. Parkinson's disease manifests with orthostatic hypotension and cardiac sympathetic denervation, significantly contributing to morbidity. Additionally, multiple sclerosis and Alzheimer's disease exhibit cardiovascular autonomic dysfunction and heightened cardiovascular risk, underscoring the need for proactive management strategies. Mechanistically, these conditions disrupt autonomic nervous system regulation, induce chronic inflammation, and may share genetic susceptibilities, each contributing to cardiovascular pathology. Effective management of these complexities requires an integrative approach that includes risk factor modification, pharmacotherapy, lifestyle interventions, and comprehensive patient education. Future research directions include identifying novel therapeutic targets, conducting large-scale clinical trials, and investigating genetic biomarkers to individualize treatment strategies. By addressing the multifaceted interactions between neurological disorders and cardiovascular health, healthcare providers can optimize patient care, reducing cardiovascular morbidity and mortality in this vulnerable population. [ABSTRACT FROM AUTHOR]

Cardiovascular complications of Brucellosis are not common and affecting less than 2% of cases. In clinical practice, endocarditis is the most frequent cardiovascular complication and is responsible for most of the brucellosis‐related mortality cases and usually diagnosed lately in the course of the disease with mostly aorta valve involvement. In this case report, we present the case of a 27‐year‐old woman who was admitted to the hospital with fever, sudden onset right side hemiparesis, and horizontal gaze palsy. During the stroke work up, she underwent cardiac evaluation, including echocardiography with susceptibility to septic emboli with cardiac origin, and the result indicates presence of vegetations on prosthetic aortic valve suggestive of infective endocarditis. Hopefully our patient responded well to combination of heart surgery and antibrucellosis regimen and was finally discharged with stable general condition. It is important to raise awareness of this rare but potentially serious complication of brucellosis, especially in the endemic area, and to emphasize the value of early diagnosis and treatment. [ABSTRACT FROM AUTHOR]

Simple Summary: Increasing number of hematopoietic stem cell transplantation (HSCT) and prolonged survival rates of these patients lead to the increase of cancer therapy-related dysfunction (CRTCD) as well. The study aimed to determine the prevalence of subclinical CTRCD in HSCT patients 12 months after HSCT and to assess the impact of clinical factors on the development of CTRCD. The study involved 55 patients who had undergone either autologous or allogeneic HSCT. Echocardiography scans were performed to check the patients' cardiac function before the transplant and again 12 months after. The study revealed that asymptomatic CTRCD was found in 27.3% of the patients 12 months after HSCT. The BEAM chemotherapy conditioning protocol following prior anthracycline use were identified as factors contributing to the development of CTRCD, therefore, these patients should undergo closer follow-up and start cardioprotective treatment when indicated. Background: Hematopoietic stem cell transplantation (HSCT) is a potentially curative procedure that is used in various hematological malignancies. However, among an increasing number of HSCT, the amount of cancer therapy-related cardiac dysfunction (CTRCD) is increasing as well. This study aimed to determine the prevalence of subclinical CTRCD in HSCT patients 12 months after HSCT and to assess the impact of clinical factors on the development of CTRCD. Material and Methods: We included 55 patients who underwent autologous or allogeneic HSCT. The patients were assessed using an echocardiography method before and 12 months after a HSCT procedure. Results: Our study revealed that during the 12-month follow-up period, asymptomatic CTRCD was observed in 15 patients (27.3%), 6 experienced moderate CTRCD, and 9 experienced mild CTRCD. Patients with previous use of anthracyclines tended to have CTRCD more often: nine patients (60%) in the CTRCD group and nine patients (22.5%) in non-CTRCD group. Patients who received the BEAM regimen for conditioning also experienced CTRCD more often: five patients (33.3%) in CTRCD group vs. two patients (5%) in the non-CTRCD group. Conclusions: Our study showed that asymptomatic CTRCD was found in 27.3% of the patients 12 months after HSCT. The BEAM chemotherapy conditioning protocol following prior anthracycline use were identified as factors contributing to the development of CTRCD. [ABSTRACT FROM AUTHOR]

Empagliflozin and dapagliflozin exert their effects by inhibiting sodium glucose cotransporter 2 (SGLT2), which inhibits glucose absorption from renal tubules. This class of drugs has also been demonstrated in studies to be protective against cardiovascular complications associated with type 2 diabetes mellitus (T2DM). Even in cases without T2DM, they have clinical utility due to their cardioprotective effects. The effects of empagliflozin and dapagliflozin on cardiovascular disorders remain incompletely understood. MicroRNAs (miRNAs) represent a class of small, non-coding RNA molecules that have been implicated in the pathogenesis of cardiovascular damage. miRNA expressions increase or decrease due to hyperglycemia and oxidative stress that occur in T2DM. This study intended to explore the SGLT2 inhibitor effects on miR-133a expressions in diabetic heart tissue by establishing a streptozotocin (STZ)/nicotinamide (NA)-induced diabetic rat model. Also, antioxidant activities were investigated in the heart and aorta tissue. Male-female Sprague-Dawley rats were injected with NA (100 mg/kg) and STZ (55 mg/kg) intraperitoneally (i.p.) respectively. One week after induction T2DM, treatments were carried out for four weeks. At the and of the treatment, the heart and thoracic aortic tissues of rats were removed. In the heart tissue glutathione (GSH), lipid peroxides (LPO), and myeloperoxidase (MPO) levels, and in the aorta tissue GSH and LPO levels were determined by fluorences method. miR-133a expression changes were assessed in the heart tissue by RT-PCR analyses. According to our results, dapagliflozin showed an antioxidant effect by increasing GSH levels in the heart (p<0.01) and aorta tissue more than empagliflozin. miR-133a expressions increased in the T2DM group and decreased in the EMPA (p<0.05) and DAPA groups (p<0.01). Studies on miR-133a expressions in different diabetes models are needed. [ABSTRACT FROM AUTHOR]

Background: In this current state, Type 2 Diabetes Mellitus (T2DM) is more prevalent in the population, and metformin is used as a first-line medication for treating it, but gradually prevalence and incident rate of T2DM is increased. There was an upsurge in the utilization of alternative therapies in managing of diabetes. Especially in diabetes, Herbal medicines are considered safe and reliable by the majority of the population. This research aims to estimate the safety and efficacy of poly herbal metabolite compounds of Cresvin beta capsules in adults with T2DM. Methods: In this study, 60 T2DM patients aged 18-60 years were randomly assigned to Groups A (30), receiving Metformin 500 mg twice a day after food, and Group B (30), receiving Cresvin beta capsule 500 mg twice a day, after food in a prospective, randomized and open-label clinical study. The in-silico simulation study was performed on selected plants major compounds on target protein Insulin-like Growth Factor-1 (1K3A). Results: The Cresvin beta is found to be safe and effective in the management of T2DM. The FBS, PPBS and HbA1c were significantly lowered (p<0.001) in post-treatment in both the Metformin and Cresvin beta capsules. Similarly, the levels of IGF1, adiponectin, EL-1, IL-6, and TNF-α showed significant alteration (p<0.001) after the treatment. The alterations found in the post-treatment results of Cresvin beta, including the reduced levels of creatinine and triglycerides, express the efficacy. Conclusion: The research results conclude, that the Cresvin beta capsule would be one of the suitable choices for increasing the efficacy in the management of diabetes mellitus. [ABSTRACT FROM AUTHOR]

Key Clinical Message: This case report highlights dilated cardiomyopathy as a cardiovascular complication in autoimmune polyendocrine syndrome type 1 (APS‐1), emphasizing the need for early recognition and a multidisciplinary approach. Comprehensive care and regular follow‐up are crucial in managing these atypical presentations to optimize patient outcomes. APS‐1, also known as Whitaker syndrome, is characterized by a triad of mucocutaneous candidiasis, adrenal insufficiency, and hypoparathyroidism. This rare autosomal recessive disorder results from mutations in the autoimmune regulator (AIRE) gene. Cardiovascular and pulmonary manifestations in APS‐1 are infrequently reported in the literature. We present a case of a 28‐year‐old male who presented with shortness of breath and pedal edema. Physical examination revealed alopecia, absence of eyebrows, hyperpigmentation on joints, oral candidiasis, and nail dystrophy. Echocardiography demonstrated dilated cardiomyopathy (DCM) and pericardial effusion. Chest x‐ray showed left‐sided pleural effusion. Laboratory investigations revealed hypocalcemia, hyperphosphatemia, low parathyroid hormone (PTH), low cortisol, and high adrenocorticotropic hormone (ACTH) levels. The combination of chronic mucocutaneous candidiasis (CMC), hypoparathyroidism, and adrenal insufficiency confirmed the diagnosis of APS‐1. To the best of our knowledge, this is the first Pakistani and second worldwide reported case of APS‐1 presenting with such a combination of manifestations. Early recognition and multidisciplinary management are crucial for improving outcomes in these patients. [ABSTRACT FROM AUTHOR]

Background: Patients with end-stage renal disease (ESRD) on dialysis exhibit a significantly higher risk of coronary artery calcification (CAC) than age-matched normal individuals, contributing to elevated cardiovascular morbidity and mortality. Aims and Objectives: This study designed to assess the prevalence of CAC in ESRD patients on dialysis and identify associated risk factors. Materials and Methods: Fifty ESRD patients undergoing maintenance dialysis and twenty normal subjects were included in this cross-sectional observational study. Serum calcium, phosphate, and parathyroid hormone were measured in all ESRD patients and normal controls. Multi Row Spiral Computed Tomography was performed to determine CAC scoring (CACS). Results: CACS was significantly higher in ESRD patients compared to normal subjects (mean CACS: 91.4±32.7 vs. 7.75±9.5 Agatston units, P<0.05). Elevated levels of calcium phosphate products, serum leptin, intact parathyroid hormone (iPTH), presence of diabetes mellitus, and longer duration of dialysis were correlated with increased incidence of CACS in ESRD patients, as indicated by higher odd's ratios ranged from 1.10 to 6.93. Conclusion: CAC is highly prevalent in ESRD patients on dialysis, emphasizing the need for stringent risk factor management. Our findings suggest that controlling calcium phosphate product, serum leptin, age, iPTH levels, and duration of dialysis may reduce CAC burden in this population, potentially mitigating cardiovascular risk and improving outcomes. [ABSTRACT FROM AUTHOR]

The pathophysiological mechanisms of cardiovascular disease and microvascular complications in diabetes have been extensively studied, but effective methods of prevention and treatment are still lacking. In recent years, DNA methylation, histone modifications, and non-coding RNAs have arisen as possible mechanisms involved in the development, maintenance, and progression of micro- and macro-vascular complications of diabetes. Epigenetic changes have the characteristic of being heritable or deletable. For this reason, they are now being studied as a therapeutic target for the treatment of diabetes and the prevention or for slowing down its complications, aiming to alleviate the personal and social burden of the disease. This review addresses current knowledge of the pathophysiological links between diabetes and cardiovascular complications, focusing on the role of epigenetic modifications, including DNA methylation and histone modifications. In addition, although the treatment of complications of diabetes with "epidrugs" is still far from being a reality and faces several challenges, we present the most promising molecules and approaches in this field. [ABSTRACT FROM AUTHOR]

Introduction: Anorexia Nervosa (AN) is a complex psychiatric illness, characterized by a high risk of developing cardiovascular complications. Given the high risk of vascular diseases in patients with AN, we can assume that patients with severe AN have a high risk of developing ischemic stroke. However, to the best of our knowledge, no reports of patients with AN presenting with ischemic stroke have been published, other than a report of the development of IS during refeeding therapy in patients with severe AN. Case presentation: The present case report is aimed at describing the characteristics of an ischemic stroke occurring in a 19-year-old university student who had a 6-month history of AN. She was a non-smoker, had no relevant medical history and no family history of stroke. Upon hospital admission due to symptoms of stroke (aphasia and facial droop), she exhibited severe malnutrition with a BMI of 12.8 kg/m2. Computerized tomography imaging revealed occlusion of the left M2 branch and a congruous extensive area of hypoperfusion. Further investigations ruled out all common causes of stroke: she had no vascular stenosis, no heart diseases or arrhythmias, and no shunts, and gave negative results in autoimmune, toxicological and thrombophilia screenings. Conclusion: Clinicians should suspect development of severe complications, including ischemic stroke, in patients with severe AN. Further extensive group studies or group-based studies are needed to elucidate the etiology of ischemic stroke in patients with severe AN. This will enable us to develop more precise and effective interventions. [ABSTRACT FROM AUTHOR]

Background: The COVID-19 pandemic, caused by SARS-CoV-2, has significantly impacted global health. COVID-19 primarily affects the respiratory system but also has notable cardiovascular implications. Patients with preexisting cardiovascular disease (CVD) or risk factors are at a heightened risk of severe complications and poor outcomes. This study aims to identify and evaluate the cardiovascular complications in symptomatic COVID-19 patients and assess the impact on disease outcomes. Methods: A retrospective, observational study was conducted on 100 COVID-19 patients confirmed via RT-PCR from June to December 2021. The patients were divided into two groups: Group A (n=25) for risk scoring and Group B (n=75) to analyze various risk factors. Exclusion criteria included patients under 18, pregnant women, and those with recent or known cardiovascular events. Data collected encompassed demographics, vital signs, symptoms, comorbidities, and laboratory results. Cardiovascular complications assessed included acute myocardial infarction, acute myocardial injury, new or worsening heart failure, de novo arrhythmias, and deep vein thrombosis. Statistical analyses were performed using online tools, with significance set at p<0.05. Results: Patients experiencing cardiovascular events in Group A had a significantly higher mean age (64.53 years) compared to those without events (53.1 years) (p<0.001), and a larger proportion were male (p<0.001). Symptoms like cough (p=0.002), fever (p=0.031), and shortness of breath (p=0.076) were more prevalent in the CV event group. Comorbidities such as diabetes mellitus (p=0.036) and coronary heart disease (CHD) (p<0.001) were also more common among those with cardiovascular complications. Multivariate analysis identified ten significant risk factors: male sex, age ≥60 years, cough, CHD, low lymphocyte count, high blood urea nitrogen, reduced eGFR, prolonged APTT, elevated D-dimer, and elevated procalcitonin levels. Conclusion: The study identified key risk factors for cardiovascular complications in COVID-19 patients, including male gender, older age, preexisting CHD, and specific laboratory markers. These findings underscore the importance of early identification and management of at-risk patients to improve outcomes. Further research is necessary to validate these risk factors and refine predictive models. [ABSTRACT FROM AUTHOR]

Simple Summary: This is a scoping study aiming to extensively assess and explore the degree of cardiotoxicity in patients with Acute Myeloid Leukemia (AML) that can be caused due to pharmaceutical treatments. Many pharmacological regiments used can potentially cause cardiotoxicity in AML patients, but it is understandable that being familiar with all the available treatment options available and every potential adverse effect is impossible before the initiation of the therapy. However, hematologists and, in general, physicians should try to be updated with the most recent information released to improve the quality of life of their patients and minimize the risk of additional complications. Correct communication and collaboration between hematologists and cardiologists is of paramount importance and a huge advantage that can yield promising results, utilizing both cardiology imaging techniques, such as cardiac ultrasound, which is an easy and cost-effective means of instant diagnosis and staging the suspected complication, and serum cardiac biomarkers, according to current cardio-oncology guidelines. Introduction: According to the National Cancer Institute of the NIH, acute myeloid leukemia (AML) is a rapidly growing cancer with a large quantity of myeloblasts. AML is most often observed in adults over the age of 35, accounting for 1% of all cancer types. In 2023, the number of new cases being reported was estimated to reach around 20,380 in total and the rate of mortality in the same year was 1.9%, or 11,310 cases, in the US. Purpose: This scoping study aims to extensively assess and explore the degree of cardiotoxicity in patients with AML that can be caused due to pharmaceutical treatments prescribed by hematologists. This is achieved by performing extensive searches of different scientific databases including PubMed, Scopus, and ScienceDirect. Results: A variety of options are available that are summarized in tables included herein, with each having their advantages and risks of adverse effects, among these being cardiotoxicity. Important medications found to play a significant role include gemtuzumab ozogamicin, venetoclax, and vyxeos. Conclusions: It is understandable that being familiar with all the treatment options available and every potential adverse effect is impossible. However, hematologists and, in general, physicians must try to be updated with the most recent information released to improve the quality of life of their patients and minimize the risk of additional complications. [ABSTRACT FROM AUTHOR]

Summary: Cardiovascular complications after major surgery are associated with increases in morbidity and mortality. There is confusion over definitions of cardiac injury or complications, and variability in the assessment and management of patients. This international prospective cohort study aimed to define the incidence and timing of these complications and to investigate their impact on 30‐day all‐cause mortality. We performed a prospective, international cohort study between January 2022 and May 2022. Data were collected on consecutive patients undergoing major abdominal surgery in 446 hospitals from 28 countries across Europe. The primary outcome measure was cardiovascular complications as defined by the Standardised Endpoints for Perioperative Medicine‐Core Outcome Measures for Perioperative and Anaesthetic Care initiative up to 30 days after surgery. The secondary outcome was 30‐day postoperative mortality. This study included 24,203 patients, of whom 611 (2.5%) developed cardiovascular complications. In total, 458 (1.9%) patients died within 30 days of surgery, of which 123 (26.9%) deaths were judged to be cardiac‐related. Mortality rates were higher in patients who developed postoperative cardiovascular complications than in those who did not (19.8% vs. 1.4%), which persisted after risk adjustment (hazard ratio (95%CI) 4.15 (3.14–5.48)). We estimated an absolute risk reduction (95%CI) of 0.4 (0.3–0.5) in mortality in the absence of all cardiovascular complications. This would confer a relative risk reduction in mortality of 21.1% if all cardiovascular complications were prevented. Postoperative cardiovascular complications are relatively common and occur early after major abdominal surgery. However, over 1 in 5 postoperative deaths were attributable to these complications, highlighting an important area for future randomised trials. [ABSTRACT FROM AUTHOR]

Introduction: Helicobacter pylori (H. pylori), despite its high prevalence in the Indian population, has been subjected to limited studies concerning its potential role as a risk factor for Metabolic Syndrome (MetS) and Insulin Resistance (IR). Proposed mechanisms include inflammatory mediators, atherogenic lipid profiles, and vasoconstriction. Aim: To determine the association between H. pylori infection and MetS components, focusing on Highly sensitive C-Reactive Protein (hs-CRP) levels, to enhance understanding and management of these conditions. Materials and Methods: This cross-sectional study was conducted at the Department of Medicine, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Pimpri, Pune, Maharashtra, India spanning from September 2017 to August 2019. This study involved 100 dyspeptic patients aged 18 years or older undergoing upper Gastrointestinal (GI) endoscopy. Data collection included fasting/postprandial blood parameters, serum lipids, hs-CRP, and H. pylori detection via both rapid urease test and Histopathological Examination (HPE). Physical assessments covered height, weight, Waist Circumference (WC), and blood pressure. MetS was evaluated using the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria. Statistical analysis employed unpaired t-tests, Chi-square tests, and Fisher-Exact tests using IBM Statistical Package for Social Sciences (SPSS) version 21.0. Results: The study of 100 dyspeptic patients, predominantly females, revealed a significant association between H. pylori infection and MetS (p-value<0.001). H. pylori infection was associated with elevated fasting glucose (90.24%) and triglycerides (90.24%) (p-value<0.001). Additionally, individuals with H. pylori infection exhibited higher inflammatory markers (p-value 0.0029). Conclusion: The above findings underscore the potential role of H. pylori as a risk factor for MetS and highlight the need for further research to elucidate mechanisms and implications for preventive strategies and clinical management, offering avenues for improved patient care and outcomes, particularly in addressing cardiovascular health. [ABSTRACT FROM AUTHOR]

Introduction: heart disease is the leading cause of death in the world for both men and women. The presentation of ischemic heart disease varies depending on multiple factors, including gender. Materials and method: observational, cross-sectional study with an analytical component of all patients admitted with ACS at the Comandante Manuel Fajardo Clinical-Surgical Teaching Hospital, between January 2016 and December 2020. Results: female patients had a median age of 73 (IQR: 62-80) significantly higher than the male gender; with a higher prevalence of arterial hypertension and diabetes mellitus (n = 353 and n = 143 respectively and p < 0.01). Age, creatinine value, and STEACS were identified as triggering factors for cardiac complications (RR: 1.01; 95% CI: 1.00-1.07; p = 0.03; RR: 1.01; 95% CI: 1.00-1.02; p = 0.01; and RR: 2.77; 95% CI: 1.31-5.87; p = 0.02 respectively). Conclusions: women with ACS were older than men, with a higher prevalence of arterial hypertension and diabetes mellitus, while the predictive variables of intrahospital cardiovascular complications identified were age, serum creatinine value, and ACS with ST elevation. [ABSTRACT FROM AUTHOR]

In this edition of the journal, the Perioperative Quality Initiative (POQI) present three manuscripts describing the physiology, assessment, and management of right ventricular dysfunction (RVD) as pertains to the perioperative setting. This narrative review seeks to provide context for these manuscripts, discussing the epidemiology of perioperative RVD focussing on definition, risk factors, and clinical implications. Throughout the perioperative period, there are many potential risk factors/insults predisposing to perioperative RVD including pre-existing RVD, fluid overload, myocardial ischaemia, pulmonary embolism, lung injury, mechanical ventilation, hypoxia and hypercarbia, lung resection, medullary reaming and cement implantation, cardiac surgery, cardiopulmonary bypass, heart and lung transplantation, and left ventricular assist device implantation. There has however been little systematic attempt to quantify the incidence of perioperative RVD. What limited data exists has assessed perioperative RVD using echocardiography, cardiovascular magnetic resonance, and pulmonary artery catheterisation but is beset by challenges resulting from the inconsistencies in RVD definitions. Alongside differences in patient and surgical risk profile, this leads to wide variation in the incidence estimate. Data concerning the clinical implications of perioperative RVD is even more scarce, though there is evidence to suggest RVD is associated with atrial arrhythmias and prolonged length of critical care stay following thoracic surgery, increased need for inotropic support in revision orthopaedic surgery, and increased critical care requirement and mortality following cardiac surgery. Acute manifestations of RVD result from low cardiac output or systemic venous congestion, which are non-specific to the diagnosis of RVD. As such, RVD is easily overlooked, and the relative contribution of RV dysfunction to postoperative morbidity is likely to be underestimated. We applaud the POQI group for highlighting this important condition. There is undoubtedly a need for further study of the RV in the perioperative period in addition to solutions for perioperative risk prediction and management strategies. There is much to understand, study, and trial in this area, but importantly for our patients, we are increasingly recognising the importance of these uncertainties. [ABSTRACT FROM AUTHOR]

Dyslipidemia caused by abnormal lipid profiles significantly increases the risk of cardiovascular disease (CVD) in individuals with diabetes. Effective management necessitates a comprehensive approach that encompasses lifestyle modifications and pharmacological intervention. Lifestyle adjustments such as adopting a healthy diet and engaging in regular physical activity play a crucial role in managing dyslipidemia. Avoiding foods high in saturated fat, trans fat, and cholesterol, while incorporating high-fiber foods and omega-3 fatty acids, helps regulate lipid profiles. Regular exercise increases high-density lipoprotein (HDL) cholesterol levels, promotes weight loss, and aids in managing dyslipidemia. While behavioral changes are beneficial, pharmacological treatments are pivotal. Statins are the cornerstone for managing dyslipidemia in diabetic patients, regardless of standard lipid levels, due to their ability to lower low-density lipoprotein (LDL) cholesterol levels. Additional lipid-lowering agents such as ezetimibe, bile acid sequestrants, and PCSK9 inhibitors may complement treatment strategies to improve lipid profiles. The advancements include new formulations of antidiabetic medications that demonstrate favorable effects on lipid parameters in diabetic patients. Sodiumglucose co-transporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) not only provide cardiovascular benefits but also aid in lowering lipid levels. SGLT-2 inhibitors reduce LDL cholesterol and triglyceride levels, while GLP-1 RAs primarily target triglycerides and LDL cholesterol levels. [ABSTRACT FROM AUTHOR]

Introduction: The typical complications considered in the paper include cardiovascular, neurological, respiratory, and vascular thrombosis-related complications. Aim of the research: To analyse the complications induced by COVID-19. Material and Methods: The authors performed a thorough systematic review in databases related to COVID complications, as well as scientific articles and publications. The analysis focused on original research on post-COVID-19 complications, which was an inclusion criterion. Among the papers selected for analysis were surveys that involved patients who had undergone COVID-19 infection and related complications. Many papers were cross-sectional studies. Most studies used the PAPI questionnaire, which is the most common research method when quantitative techniques are concerned. The studies were analysed using a meta-analysis involving a PRISMA method. Results: The studies indicated a correlation between the incidence of COVID-19 and the complications that arose from it. Conclusions: The results obtained suggest multifaceted monitoring of post-COVID-19 complications in the longer term. [ABSTRACT FROM AUTHOR]

This article provides a comprehensive review of Marfan Syndrome (MFS), covering its epidemiology, etiology, clinical presentations, diagnostics, complications, and treatment modalities. The Ghent II Nosology of MFS criteria are crucial in MFS diagnosis, guiding clinicians in identifying high-risk patients. Nursing implications underscore the importance of screenings, assessments, and close follow-ups to optimize the continuum of care for individuals with MFS. This article provides a comprehensive review of Marfan Syndrome, covering its epidemiology, etiology, clinical presentations, diagnostics, complications, and treatment modalities. [ABSTRACT FROM AUTHOR]

• MASLD is the most common liver disease worldwide and the most growing liver transplant indication in Western countries. • The natural course of the disease exhibits significant dynamism and bidirectionality. • The fibrosis stage is the most accurate predictor of mortality. • Cardiovascular disease and associated events are the predominant contributing factors to death among MASLD patients. • MASH-related decompensated cirrhosis appears to have worse prognosis than decompensated cirrhosis of other etiologies. Metabolic dysfunction-associated steatotic liver disease (MASLD), which has been the term for non-alcoholic fatty liver disease (NAFLD) since June 2023, represents the most common liver disease worldwide and is a leading cause of liver-related morbidity and mortality. A thorough knowledge of the disease's natural history is required to promptly stratify patients' risks, since MASLD is a multifaceted disorder with a broad range of clinical phenotypes. The histological disease spectrum ranges from isolated hepatic steatosis, currently named as metabolic dysfunction-associated steatotic liver (MASL), to metabolic dysfunction-associated steatohepatitis (MASH) and eventually may accumulate hepatic fibrosis and develop cirrhosis and/or hepatocellular carcinoma (HCC). Several risk factors for fibrosis progression have been identified, while the disease's progression displays notable dynamism and bidirectionality. When compared to the general population, all MASLD histological stages are substantially related with greater overall mortality, and this association exhibits a disease severity-dependent pattern. Interestingly, the fibrosis stage is the most accurate predictor of mortality among MASLD patients. The mortality attributed to MASLD predominantly stems from issues linked with the liver and cardiovascular system, as well as HCC and extrahepatic cancers. In light of the disease natural course, it is crucial to prioritize the identification of at-risk patients for disease progression in order to effectively address and change modifiable risk factors, hence mitigating disease complications. Further investigation is required to define the phenotype of rapid progressors more precisely as well as to improve risk stratification for HCC in non-cirrhotic individuals. [ABSTRACT FROM AUTHOR]

Background: Cushing's disease (CD) is associated with a specific form of metabolic syndrome that includes visceral obesity, which may affect cardiovascular hemodynamics by stimulating hypercortisolism-related metabolic activity. The purpose of this study was to evaluate the relationship between obesity and the hemodynamic profile of patients with CD. Methods: This prospective clinical study involved a hemodynamic status assessment of 54 patients newly diagnosed with CD with no significant comorbidities (mean age of 41 years). The assessments included impedance cardiography (ICG) to assess such parameters as stroke index (SI), cardiac index (CI), velocity index (VI), acceleration index (ACI), Heather index (HI), systemic vascular resistance index (SVRI), and total arterial compliance index (TACI) as well as applanation tonometry to assess such parameters as central pulse pressure (CPP) and augmentation index (AI). These assessments were complemented by echocardiography to assess cardiac structure and function. Results: Compared with CD patients without obesity, individuals with CD and obesity (defined as a body mass index ≥ 30 kg/m2) exhibited significantly lower values of ICG parameters characterizing the pumping function of the heart (VI: 37.0 ± 9.5 vs. 47.2 ± 14.3 × 1*1000−1*s−1, p = 0.006; ACI: 58.7 ± 23.5 vs. 76.0 ± 23.5 × 1/100/s2, p = 0.005; HI: 11.1 ± 3.5 vs. 14.6 ± 5.5 × Ohm/s2, p = 0.01), whereas echocardiography in obese patients showed larger heart chamber sizes and a higher left ventricular mass index. No significant intergroup differences in blood pressure, heart rate, LVEF, GLS, TACI, CPP, or AI were noted. Conclusions: Hemodynamic changes associated with obesity already occur at an early stage of CD and manifest via significantly lower values of the ICG parameters illustrating the heart's function as a pump, despite the normal function of the left ventricle in echocardiography. [ABSTRACT FROM AUTHOR]

Background: We prospectively evaluated the predictive value of multiparametric cardiac magnetic resonance (CMR) for cardiovascular complications in non-transfusion-dependent β-thalassemia (β-NTDT) patients who started regular transfusions in late childhood/adulthood (neo β-TDT). Methods: We considered 180 patients (38.25 ± 11.24 years; 106 females). CMR was used to quantify cardiac iron overload, biventricular function, and atrial dimensions, and to detect left ventricular (LV) replacement fibrosis. Results: During a mean follow-up of 76.87 ± 41.60 months, 18 (10.0%) cardiovascular events were recorded: 2 heart failures, 13 arrhythmias (10 supraventricular), and 3 cases of pulmonary hypertension. Right ventricular (RV) end-diastolic volume index (EDVI), RV mass index (MI), LV replacement fibrosis, and right atrial (RA) area index emerged as significant univariate prognosticators of cardiovascular complications. The low number of events prevented us from performing a multivariable analysis including all univariable predictors simultaneously. Firstly, a multivariable analysis including the two RV size parameters (mass and volume) was carried out, and only the RV MI was proven to independently predict cardiovascular diseases. Then, a multivariable analysis, including RV MI, RA atrial area, and LV replacement fibrosis, was conducted. In this model, RV MI and LV replacement fibrosis emerged as independent predictors of cardiovascular outcomes (RV MI: hazard ratio (HR) = 1.18; LV replacement fibrosis: HR = 6.26). Conclusions: Our results highlight the importance of CMR in cardiovascular risk stratification. [ABSTRACT FROM AUTHOR]

The clinical spectrum of Coronavirus disease 2019 (COVID-19) varies from asymptomatic infection to severe disease with multiorgan dysfunction. Cardiovascular involvement is common and in rare cases can lead to serious complications, such as fulminant myocarditis. The clinical course of COVID-19 myocarditis varies from complete recovery to death in rare cases. The pathophysiology of COVID-19-related myocarditis is still unclear but is believed to involve direct viral injury and cardiac damage due to the host's immune response. Guidelines on the management of COVID-19-related myocarditis are yet to be established. We present here the case of a male patient in his early fifties admitted with life-threatening myocarditis in the course of COVID-19 infection who was successfully treated and recovered without any sequelae. [ABSTRACT FROM AUTHOR]

Background: Patients with diabetes demonstrate early left ventricular systolic dysfunction. Notably reduced global longitudinal strain (GLS) is related to poor outcomes, the underlying pathophysiology is however still not clearly understood. We hypothesized that pathophysiologic changes with microvascular dysfunction and interstitial fibrosis contribute to reduced strain. Methods: 211 patients with type 2 diabetes and 25 control subjects underwent comprehensive cardiovascular phenotyping by magnetic resonance imaging. Myocardial blood flow (MBF), perfusion reserve (MPR), extracellular volume (ECV), and 3D feature tracking GLS and global circumferential (GCS) and radial strain (GRS) were quantified. Results: Patients (median age 57 [IQR 50, 67] years, 70% males) had a median diabetes duration of 12 [IQR 6, 18] years. Compared to control subjects GLS, GCS, and GRS were reduced in the total diabetes cohort, and GLS was also reduced in the sub-group of patients without diabetic complications compared to control subjects (controls − 13.9 ± 2.0%, total cohort − 11.6 ± 3.0%; subgroup − 12.3 ± 2.6%, all p < 0.05). Reduced GLS, but not GCS or GRS, was associated with classic diabetes complications of albuminuria (UACR ≥ 30 mg/g) [β (95% CI) 1.09 (0.22–1.96)] and autonomic neuropathy [β (95% CI) 1.43 (0.54–2.31)] but GLS was not associated with retinopathy or peripheral neuropathy. Independently of ECV, a 10% increase in MBF at stress and MPR was associated with higher GLS [multivariable regression adjusted for age, sex, hypertension, smoking, and ECV: MBF stress (β (95% CI) − 0.2 (− 0.3 to − 0.08), MPR (β (95% CI) − 0.5 (− 0.8 to − 0.3), p < 0.001 for both]. A 10% increase in ECV was associated with a decrease in GLS in univariable [β (95% CI) 0.6 (0.2 to 1.1)] and multivariable regression, but this was abolished when adjusted for MPR [multivariable regression adjusted for age, sex, hypertension, smoking, and MPR (β (95% CI) 0.1 (− 0.3 to 0.6)]. On the receiver operating characteristics curve, GLS showed a moderate ability to discriminate a significantly lowered stress MBF (AUC 0.72) and MPR (AUC 0.73). Conclusions: Myocardial microvascular dysfunction was independent of ECV, a biomarker of myocardial fibrosis, associated with GLS. Further, 3D GLS could be a potential screening tool for myocardial microvascular dysfunction. Future directions should focus on confirming these results in longitudinal and/or interventional studies. [ABSTRACT FROM AUTHOR]

Introduction: Abdominal oncologic surgeries pose significant risks due to the complexity of the surgery and patients' often weakened health, multiple comorbidities, and increased perioperative hazards. Hypotension is a major risk factor for perioperative cardiovascular complications, necessitating individualized management in modern anesthesiology. Aim: This study aimed to determine the dynamics of changes in troponin and NTproBNP levels during the first two postoperative days in patients undergoing major cancer abdominal surgery with advanced hemodynamic monitoring including The AcumenTM Hypotension Prediction Index software (HPI) (Edwards Lifesciences, Irvine, CA, USA) and their association with the occurrence of postoperative cardiovascular complications. Methods: A prospective study was conducted, including 50 patients scheduled for abdominal cancer surgery who, due to the overall risk of perioperative complications (ASA class 3 or 4), were monitored using the HPI software. Hypotension was qualified as at least one ≥ 1 min episode of a MAP < 65 mm Hg. Preoperatively and 24 and 48 h after the procedure, the levels of NTproBNP and troponin were measured, and an ECG was performed. Results: We analyzed data from 46 patients and found that 82% experienced at least one episode of low blood pressure (MAP < 65 mmHg). However, the quality indices of hypotension were low, with a median time-weighted average MAP < 65 mmHg of 0.085 (0.03–0.19) mmHg and a median of 2 (2–1.17) minutes spent below MAP < 65 mmHg. Although the incidence of perioperative myocardial injury was 10%, there was no evidence to suggest a relationship with hypotension. Acute kidney injury was seen in 23.9% of patients, and it was significantly associated with a number of episodes of MAP < 50 mmHg. Levels of NTproBNP were significantly higher on the first postoperative day compared to preoperative values (285.8 [IQR: 679.8] vs. 183.9 [IQR: 428.1] pg/mL, p < 0.001). However, they decreased on the second day (276.65 [IQR: 609.4] pg/mL, p = 0.154). The dynamics of NTproBNP were similar for patients with and without heart failure, although those with heart failure had significantly higher preoperative concentrations (435.9 [IQR: 711.15] vs. 87 [IQR: 232.2] pg/mL, p < 0.001). Patients undergoing laparoscopic surgery showed a statistically significant increase in NTproBNP. Conclusions: This study suggests that advanced HPI monitoring in abdominal cancer surgery effectively minimizes intraoperative hypotension with no significant NTproBNP or troponin perioperative dynamics, irrespective of preoperative heart failure. [ABSTRACT FROM AUTHOR]

The paper examines the relationship of meteorological factors with the development of cardiovascular complications. Statistically significant seasonal fluctuations in the level and variability of blood pressure, heart rate, cholesterol, glucose, and body mass have been revealed. The variability of blood pressure is maximal in winter and minimal in summer. It is known that heat and cold waves are associated with an increase in mortality and cardiovascular complications, including hypertensive crises. Their frequency depends on the level of cardiovascular risk of a patient and is maximal in people with coronary heart disease, cerebrovascular disease, and type 2 diabetes. The influence of such poorly predictable factors as temperature waves and magnetic storms has been less studied. It seems promising to examine the relationship of the variability of blood pressure and complications of arterial hypertension with meteorological factors using the method for remote blood pressure monitoring, which is currently actively implemented in the regions of the Russian Federation. [ABSTRACT FROM AUTHOR]

Background: Acromegaly is a rare, chronic disease that involves structural and functional abnormalities of the cardiovascular system. Acromegaly likely affects interactions between the cardiovascular system and the autonomic nervous system (ANS). Therefore, assessing the relationship between sympathetic–parasympathetic balance by analyzing heart rate variability (HRV) and the hemodynamic profile via impedance cardiography (ICG) may be useful in learning the exact nature of interactions between the ANS and the cardiovascular system. The purpose of this study was to assess a possible association between HRV and ICG-based parameters of cardiac function in patients newly diagnosed with acromegaly. Methods: This observational cohort study was conducted on 33 patients (18 men, mean age of 47 years) newly diagnosed with acromegaly and no significant comorbidities. A correlation analysis (Spearman's rank coefficient R) of the parameters assessed via ICG and the HRV assessed via 24 h ambulatory electrocardiography was performed. ICG assessments included the following parameters: stroke volume index (SI), cardiac index (CI), acceleration index (ACI), velocity index (VI), and Heather index (HI). The analysis of HRV included both time-domain parameters (pNN50, SDNN, SDSD, rMSSD) and frequency-domain parameters (total power (TP) and its individual frequency bands: low-frequency (LF day/night), high-frequency (HF day/night), and the LF/HF ratio (day/night)). Results: Frequency-domain HRV analysis showed the following correlations: (1) lower nighttime LF values with higher ACI (R = −0.38; p = 0.027) and HI (R = −0.46; p = 0.007) values; (2) higher nighttime HF values with higher ACI (R = 0.39; p = 0.027) and HI (R = 0.43; p = 0.014) values; (3) lower nighttime LF/HF values with higher ACI (R = −0.36; p = 0.037) and HI (R = −0.42; p = 0.014) values; (4) higher nighttime TP values with higher SI values (R = 0.35; p = 0.049). Time-domain parameters of HRV showed a significant correlation only between the nighttime values of SDSD and SI (R = 0.35; p = 0.049) and between the daytime and nighttime values of SDNN and HR (R = −0.50; p = 0.003 and R = −0.35; p = 0.046). In multivariate regression, only ACI was revealed to be independently related to HRV. Conclusions: In patients newly diagnosed with acromegaly, the relationship between the sympathetic–parasympathetic balance assessed via HRV and the hemodynamic profile assessed via ICG was revealed. Better function of the left ventricle was associated with a parasympathetic shift in the autonomic balance. [ABSTRACT FROM AUTHOR]

Introduction Cardiovascular disease (CVD) is one of the prominent causes of mortality in cases of chronic Type 2 diabetes mellitus (T2DM) patients and necessitates improving risk categorization. There are few available biomarkers that can assess preceding or current glycemic and cardiac status, but not prognosis. Serum homocysteine (Hcy) has been indicated and reported to be a likely biomarker that can detect cardiovascular complication in patients with T2DM. Methodology Present study details the comparative analysis of several biochemical and metabolic biomarkers including Hcy in T2DM patients with and without CVD complications. A total of eighty patients, n = 40 each in T2DM with CVD and T2DM without CVD, were included in the study. Patient’s preparation, blood sample collection and analyses of all biochemical, metabolic markers including Hcy were performed as per standard protocols. One way ANOVA was used for independent measures including Tukey HSD with level of significance at P< 0.05. Results Indication of hyperhomocysteinemia, was significantly apparent in patients with T2DM who have CVD, as compared to those with T2DM without CVD. All other biochemical and metabolic parameters manifested marked significant (P< 0.00001) elevations, which was more perceptible in T2DM CVD as compared to T2DM non CVD. Clinical relevance of high Hcy in blood in patients with T2DM CVD thus suggested being prominent risk factor for proceeding renal and cardiac complications. [ABSTRACT FROM AUTHOR]

Aim: Effort intolerance is frequent in patients with overweight/obesity and/or type 2 diabetes (T2D) free from cardiac and respiratory disease. We sought to quantify the independent effects of T2D and body mass index (BMI) on cardiopulmonary capacity and gain insights on the possible pathophysiology by case‐control and regression analyses. Methods: Patients at high/moderate cardiovascular risk, with or without T2D, underwent spirometry and combined echocardiography‐cardiopulmonary exercise test as part of their clinical workup. Subjects with evidence of cardiopulmonary disease were excluded. The effects of T2D and obesity were estimated by multivariable models accounting for known/potential confounders and the major pathophysiological determinants of oxygen uptake at peak exercise (VO2peak) normalized for fat‐free mass (FFM). Results: In total, 109 patients with T2D and 97 controls were included in the analysis. The two groups had similar demographic and anthropometric characteristics except for higher BMI in T2D (28.6 ± 4.6 vs. 26.3 ± 4.4 kg/m2, p =.0003) but comparable FFM. Patients with T2D achieved lower VO2peak than controls (18.5 ± 4.4 vs. 21.7 ± 8.3 ml/min/kg, p =.0006). Subclinical cardiovascular dysfunctions were observed in T2D: concentric left ventricular remodelling, autonomic dysfunction, systolic dysfunction and reduced systolic reserve. After accounting for confounders and major determinants of VO2peakFFM, T2D still displayed reduced VO2peak by 1.0 (−1.7/−0.3) ml/min/kgFFM, p =.0089, while the effect of BMI [−0.2 (−0.3/0.1) ml/min/kgFFM, p =.06 per unit increase], was largely explained by a combination of chronotropic incompetence, reduced peripheral oxygen extraction, impaired systolic reserve and ventilatory (in)efficiency. Conclusions: T2D is an independent negative determinant of VO2peak whose effect is additive to other pathophysiological determinants of oxygen uptake, including BMI. [ABSTRACT FROM AUTHOR]

Background: The estimation of Serum Cystatin C has become widely available in clinical practice. Though Cystatin C is an approved marker of renal dysfunction in diabetic population, its role is evolving as a marker of cardiovascular mortality as well as neuro-degenerative disorders like Alzheimer's disease. Aim: The present study aims to establish the predictive role of Cystatin C in cardiovascular complications and hence its role in as a marker of cardiovascular mortality in a diabetic population. Methods: 144 patients fulfilling inclusion and exclusion criteria were enrolled in the study over a period of 3 months. Details of socio-demographic data, clinical variables and biochemical parameters were collected using a semi-structured proforma specifically designed for this study. Relevant clinical tests were done and data thus collected was tabulated and analysed using SPSS. Conclusion: There is a significant correlation of elevated Serum Cystatin C and cardiovascular complications. It has a strong positive predictive value for cardiovascular mortality in diabetic population. [ABSTRACT FROM AUTHOR]

INTRODUCTION This study was carried out to assess the lipid profile and cardiovascular complications in patients with chronic kidney disease. METHODS This was a cross-sectional study carried out over a period of 2 years involving 60 patients with chronic kidney disease who were admitted to the Government General Hospital at Kurnool. Patients with bilaterally contracted kidneys, those with a GFR < 60 mL/min/1.73m² and adults aged > 18 years with a history of kidney disease for a duration of > 6 months were included in the study. RESULTS The mean total cholesterol of overall patients was 189.8 ± 14.72 mg/dl. The mean total cholesterol was significantly higher in patients with stage 5 CKD compared to stage 4 and stage 3 CKD patients. (p < 0.05; significant). The mean triglycerides of overall patients were 174.8 ± 16.29 mg/dl. There was no significant difference in mean triglycerides between different stages of CKD patients. (p > 0.05; not significant). The mean HDL-cholesterol of overall patients was 37.50 ± 7.56 mg/dl. There was no significant difference in mean HDL-cholesterol between different stages of CKD patients. (p>0.05; not significant). The mean LDL-cholesterol of overall patients was 132.2 ± 15.74 mg/dl. There was no significant difference in mean LDL-cholesterol between different stages of CKD patients. (p>0.05; not significant). The mean VLDL-cholesterol of overall patients was 37.50 ± 12.36 mg/dl. There was no significant difference in mean VLDLcholesterol between different stages of CKD patients. (p > 0.05; not significant). CONCLUSION CKD continues to be a major disease affecting males in the age group of 41 to 50 years. Dyslipidemia in the form of higher cholesterol and triglyceride levels and cardiovascular changes are observed more frequently in CKD patients, especially in stages 4 and 5. Further research is warranted towards mitigating these important risk factors in order to reduce mortality in this cohort of patients. [ABSTRACT FROM AUTHOR]

The rising prevalence of cardiovascular disease (CVD) and the impact of the SARS-CoV-2 pandemic have both led to increased mortality rates, affecting public health and the global economy. Therefore, it is essential to find accessible, non-invasive prognostic markers capable of identifying patients at high risk. One encouraging avenue of exploration is the potential of mid-regional proadrenomedullin (MR-proADM) as a biomarker in various health conditions, especially in the context of CVD and COVID-19. MR-proADM presents the ability to predict mortality, heart failure, and adverse outcomes in CVD, offering promise for improved risk assessment and treatment strategies. On the other hand, an elevated MR-proADM level is associated with disease severity and cytokine storms in patients with COVID-19, making it a predictive indicator for intensive care unit admissions and mortality rates. Moreover, MR-proADM may have relevance in long COVID, aiding in the risk assessment, triage, and monitoring of individuals at increased risk of developing prolonged cardiac issues. Our review explores the potential of MR-proADM as a predictor of enduring cardiovascular complications following COVID-19 infection. [ABSTRACT FROM AUTHOR]

Aim: To evaluate the long‐term associations between coronavirus disease 2019 (COVID‐19) and diabetes complications and mortality, in patients with diabetes. Materials and Methods: People with diabetes diagnosed with COVID‐19 infection (exposed group), from 16 March 2020 to 31 May 2021 from the UK Biobank (UKB cohort; n = 2456), and from 1 April 2020 to 31 May 2022 from the electronic health records in Hong Kong (HK cohort; n = 80 546), were recruited. Each patient was randomly matched with participants with diabetes but without COVID‐19 (unexposed group), based on age and sex (UKB, n = 41 801; HK, n = 391 849). Patients were followed for up to 18 months until 31 August 2021 for UKB, and up to 28 months until 15 August 2022 for HK. Characteristics between cohorts were further adjusted with Inverse Probability Treatment Weighting. Long‐term association of COVID‐19 with multi‐organ disease complications and all‐cause mortality after 21 days of diagnosis was evaluated by Cox regression. Results: Compared with uninfected participants, patients with COVID‐19 infection with diabetes were consistently associated with higher risks of cardiovascular diseases (coronary heart disease [CHD]: hazard ratio [HR] [UKB]: 1.6 [95% confidence interval {CI}: 1.0, 2.4], HR [HK]: 1.2 [95% CI: 1.0, 1.5]; and stroke: HR [UKB]: 2.0 [95% CI: 1.1, 3.6], HR [HK]: 1.5 [95% CI: 1.3, 1.8]), microvascular disease (end stage renal disease: HR [UKB]: 2.1 [95% CI: 1.1, 4.0], HR [HK]: 1.2 [95% CI: 1.1, 1.4]) and all‐cause mortality (HR [UKB]: 4.6 [95% CI: 3.8, 5.5], HR [HK]: 2.6 [95% CI: 2.5, 2.8]), in both cohorts. Conclusions: COVID‐19 infection is associated with long‐term increased risks of diabetes complications (especially cardiovascular complications, and mortality) in people with diabetes. Monitoring for signs/symptoms of developing these long‐term complications post‐COVID‐19 infection in the infected patient population of people with diabetes may be beneficial in minimizing their morbidity and mortality. [ABSTRACT FROM AUTHOR]

Background: Type 2 Diabetes Mellitus (T2DM) is a metabolic disorder that affects millions of people worldwide. One of the common complications associated with T2DM is hyperuricemia, which is characterized by high levels of uric acid in the blood. Hyperuricemia has been linked to various cardiovascular and renal diseases. Therefore, the assessment of serum uric acid levels in patients with T2DM is essential to identify those at risk of developing these complications. Objective: The aim of this study is to assess the serum uric acid levels in patients with T2DM attending a tertiary care hospital. Methods: This cross-sectional study was conducted in a tertiary care hospital in Mahabubabad, Telangana. A total of 100 patients diagnosed with T2DM were included in the study. The serum uric acid levels were measured using standard laboratory methods. Data on demographic characteristics, medical history, and medications were collected through a structured questionnaire. The data were analyzed using descriptive statistics and inferential statistics. Results: The mean age of the study participants was 57.3 years, and 55% were male. The mean serum uric acid level was 6.7 mg/dL. 41% of the participants had hyperuricemia (serum uric acid level ≥ 7.0 mg/dL). There was a significant positive correlation between serum uric acid levels and age, body mass index (BMI), fasting blood glucose (FBG), hemoglobin A1c (HbA1c), and serum creatinine levels (p < 0.05). No significant association was found between serum uric acid levels and gender or duration of diabetes. Conclusion: The study found a high prevalence of hyperuricemia in patients with T2DM attending a tertiary care hospital. Serum uric acid levels were positively associated with age, BMI, FBG, HbA1c, and serum creatinine levels. These findings suggest that routine monitoring of serum uric acid levels may be beneficial in identifying those at risk of developing cardiovascular and renal complications in patients with T2DM. Further studies with larger sample sizes are needed to confirm these findings and establish the clinical significance of these associations. [ABSTRACT FROM AUTHOR]

Background: Diabetes mellitus, characterized by elevated blood glucose levels, poses a significant global health challenge. Type 2 diabetes accounts for the majority of cases and is associated with factors such as obesity, physical inactivity, and poor dietary habits. The global burden of diabetes is substantial, contributing to major complications like blindness, kidney failure, heart attacks, stroke, and lower limb amputation. Methodology: This study investigates cardiovascular complications in 209 adult diabetic cases with a disease duration exceeding 5 years. The research, conducted at a tertiary care teaching hospital, includes a detailed clinical examination, relevant investigations, and categorization based on disease severity, control status, and treatment type. Various parameters, including fasting blood sugar, postprandial blood sugar, urine examinations, serum cholesterol levels, and hypertension classification, were assessed. Results: The study reveals that 112 cases (53.6%) exhibited cardiovascular complications, with ischemic heart disease (IHD) being the most prevalent (39.7%). The majority of patients were in the 51-60 age group, and 75.6% were male. Poor glycemic control was evident in 79.9% of cases, while 23.9% had severe diabetes. Hypertension and retinopathy were present in 30.1% and 35.8% of cases, respectively. IHD was more prevalent in males (56.6%) and the 51-60 age group. Discussion: The study establishes associations between different complications, emphasizing the frequent coexistence of various cardiovascular issues in diabetes. It explores the distribution of IHD among diabetics, with a peak in the 51-60 age group and a higher incidence in males. The severity of diabetes did not significantly influence IHD incidence. Good glycemic control demonstrated a protective effect against complications. Conclusion: This comprehensive study underscores the substantial impact of cardiovascular complications in diabetes mellitus. It highlights the importance of glycemic control, lifestyle modifications, and weight management in reducing the incidence and severity of complications. [ABSTRACT FROM AUTHOR]

Typhoid fever (TF) is a systemic infection caused by Salmonella Typhi (Salmonella Enterica) transmitted through contaminated water, food, or contact with infected individuals. In various infectious diseases, blood viscosity (BV) is affected by changes in hemoglobin concentrations and acute phase reactants. Inflammatory responses can lead to elevated plasma protein levels and further affect BV. This study aimed to investigate BV changes in patients with acute TF. A cross-sectional study was performed involving 55 patients with acute TF compared to 38 healthy controls. BV and in- flammatory parameters were measured in both groups. TF patients showed reduced blood cells compared to healthy controls (p=0.001). Additionally, plasma total protein (TP) levels significantly increased to 10.79±1.05 g/L in TF patients compared to 7.035±1.44 g/L in healthy controls (p=0.03). Hematocrit (HCT) levels were 11.67±2.89% in TF patients and 12.84±2.02% in healthy controls (p=0.07), suggesting a trend towards increased BV in TF patients. Elevated BV is involved in the pathogenesis of different inflammatory and infectious diseases. The increased BV in TF patients may raise the risk of complications. Therefore, monitoring BV might be a crucial tool in TF patients, mainly in the high-risk group, for early detection of cardiovascular complications. [ABSTRACT FROM AUTHOR]

Background and Aim Cardiovascular complications in diabetes mellitus are one of the most common complications of this disease. The aim of this study was to determine the cumulative probability of occurrence of cardiac complications in type 2 diabetes mellitus using survival analysis in patients referring to the Diabetes Clinic, Bu-Ali Hospital, Zahedan, Iran. Materials and Methods: This was a descriptive and analytical historical cohort study using the survival analysis method in 2020 on 410 patients referring to the Diabetes Clinic, Bu-Ali Hospital, Zahedan, Iran. Data were collected and analyzed using the SPSSv21 software, the statistical tests being descriptive tests, followed by the Kaplan-Meier method and the Cox proportional hazards model of survival. Results: The results of this study showed that 122 individuals (29.7%) of the diabetic patients had cardiac complications. The median survival time (in months) of the occurrence of cardiac complications was found to be related to fasting and twohour postprandial blood sugar levels (p<0.05). Further analysis of the data showed that two variables, namely fasting blood sugar and regular visits, remained in the final model of the multiple Cox regression. Conclusion: The findings of this study showed that the cardiac complications of diabetes in the population studies are relatively high. Therefore, it is essential to plan and implement interventions aiming to change lifestyle and control regularly blood pressure, cholesterol and blood sugar in the patients in order to prevent the disease and reduce complications related to diabetes. [ABSTRACT FROM AUTHOR]

• HCV infection is not associated with hepatic iron levels in TM. • Chronic HCV infection significantly increases the risk of diabetes in TM. • Chronic HCV infection is a prospective risk marker of cardiac complications in TM. No study has evaluated the effect of hepatitis C virus (HCV) infection on the wide spectrum of complications affecting patients with thalassemia. This multicenter study prospectively assessed the relationship of HCV infection with diabetes mellitus and cardiovascular complications in patients with thalassemia major (TM). We considered 1057 TM patients (539 females; 29.79±10.08 years) enrolled in the MIOT Network and categorized into 4 groups: negative patients (group 1a, N=460), patients who spontaneously cleared the virus within 6months (group 1b, N=242), patients who eradicated the virus after the treatment with antiviral therapy (group 2, N=102), and patients with chronic HCV infection (group 3, N=254). Group 1a and 1b were considered as a unique group (group 1). For both groups 1 and 3, a match 1:1 for age and sex with group 2 was performed. The effective study cohort consisted of 306 patients (three groups of 102 patients). During a mean follow-up of 67.93±39.20months, the group 3 experienced a significantly higher % increase/month in aspartate transaminase levels and left ventricular mass index than both groups 1 and 2. The changes in iron overload indexes were comparable among the three groups. Compared to group 1, the chronic HCV group showed a significantly higher risk of diabetes (hazard ratio-HR=5.33; p=0.043) and of cardiovascular diseases (HR=3.80; p=0.034). Chronic HCV infection is associated with a significant higher risk of diabetes mellitus and cardiovascular complications in TM patients and should be approached as a systemic disease in which extrahepatic complications increase the weight of its pathological burden. [Display omitted] [ABSTRACT FROM AUTHOR]

Neutrophil gelatinase-associated lipocalin (NGAL) is a 25-kDa protein that is secreted mostly by immune cells such as neutrophils, macrophages, and dendritic cells. Its production is stimulated in response to inflammation. The concentrations of NGAL can be measured in plasma, urine, and biological fluids such as peritoneal effluent. NGAL is known mainly as a biomarker of acute kidney injury and is released after tubular damage and during renal regeneration processes. NGAL is also elevated in chronic kidney disease and dialysis patients. It may play a role as a predictor of the progression of renal function decreases with complications and mortality due to kidney failure. NGAL is also useful in the diagnostic processes of cardiovascular diseases. It is highly expressed in injured heart tissue and atherosclerostic plaque; its serum concentrations correlate with the severity of heart failure and coronary artery disease. NGAL increases inflammatory states and its levels rise in arterial hypertension, obesity, diabetes, and metabolic complications such as insulin resistance, and is also involved in carcinogenesis. In this review, we present the current knowledge on NGAL and its involvement in different pathologies, especially its role in renal and cardiovascular diseases. [ABSTRACT FROM AUTHOR]

To investigate the effect of surgical intervention on 24-h ABP in children with OSA. It was hypothesized that blood pressure would improve following adenotonsillectomy. This was a two - centered investigator-blinded randomized controlled trial. Non-obese pre-pubertal children aged 6–11 years with OSA (obstructive apnea-hypopnea index, OAHI >3/h) underwent 24-h ABP monitoring at baseline and 9 months after the randomly assigned intervention, i.e. Early Surgery (ES) or Watchful Waiting (WW). Intention-to-treat analysis was performed. 137 subjects were randomized. Sixty-two (Age: 7.9y ± 1.3, 71% boys) and 47 (Age: 8.5y ± 1.6, 77% boys) participants from the ES and WW groups, respectively completed the study. Changes in ABP parameters were similar in the ES and WW groups (nighttime systolic BP z-scores: +0.03 ± 0.93 vs. −0.06 ± 1.04, p = 0.65; nighttime diastolic BP z-scores: −0.20 ± 0.95 vs. −0.02 ± 1.00, p = 0.35) despite a greater improvement in OSA in the ES group. However, a reduction in nighttime diastolic BP z-score correlated with improvements in OSA severity indexes (r = 0.21–0.22, p < 0.05), and a significant improvement in nighttime diastolic BP z-score [-0.43 ± 1.01, p = 0.027] following surgery was observed in participants with severe preoperative OSA (OAHI ≥10/h). The ES group had a significant increase in body mass index z-score after surgery [+0.27 ± 0.57, p < 0.001], which correlated with the increase in daytime systolic BP z-score (r = 0.2, p < 0.05). Surgical treatment did not lead to significant improvements in ABP in OSA children except in those with more severe disease. The improvement in BP was partially masked by the weight gain following surgery. The trial was registered with the Chinese Clinical Trial Registry (http://www.chictr.org.cn. Registration number: ChiCTR-TRC-14004131). • No significant treatment effect of adenotonsillectomy on BP was observed in OSA children. • The improvement on BP after the surgery was more prominent in children with severe OSA. • Weight gain after the surgery was associated with the increase in BP. [ABSTRACT FROM AUTHOR]

Objective: To investigate the correlation between GAL-3, Klotho, calcium and phosphorus indexes and cardiovascular complications in patients with chronic kidney disease (CKD). Methods: This is a retrospective study. Forty patients with CKD and cardiovascular complications admitted to the Affiliated Hospital of Hebei University from February 20, 2022 to February 20, 2023 were selected as the experimental group, and another 40 patients with CKD without cardiovascular complications were selected as the control group. The differences in serum Ca+2, PO-4, GAL-3 and Klotho levels between the two groups were analyzed, and the correlations between the above indicators levels and creatinine levels were analyzed. The correlation between the above indicators levels and cardiac function classification was analyzed, and analyzed the risk factors of CKD complicated with cardiovascular complications. Results: The levels of Ca+2, PO-4 and GAL-3 in the experimental group were significantly higher than those in the control group, while the level of Klotho was significantly lower than that in the control group. The levels of Ca+2 and PO-4 were positively correlated with the level of Creatinine (Cr), while the level of Klotho was negatively correlated with the Cr. The levels of Ca+2 and PO-4 were positively correlated with cardiac function classification, while the level of Klotho was negatively correlated with cardiac function classification. Logistic regression analysis showed that hypertension, BMI, Cr, Ca+2, PO-4 and VLDL were risk factors for cardiovascular complications, and Klotho level was a protective factor. Conclusion: A positive correlation can be seen between the levels of Ca+2, PO-4 and cardiac function classification in patients with CKD. Klotho is a protective factor for cardiovascular diseases. [ABSTRACT FROM AUTHOR]

Plasma soluble prorenin receptor (sPRR) displays sexual dimorphism and is higher in women with type 2 diabetes mellitus (T2DM). However, the contribution of plasma sPRR to the development of vascular complications in T2DM remains unclear. We investigated if plasma sPRR contributes to sex differences in the activation of the systemic renin-angiotensin-aldosterone system (RAAS) and vascular damage in a model of high-fat diet (HFD)-induced T2DM. Male and female C57BL/6J mice were fed either a normal fat diet (NFD) or an HFD for 28 wk to assess changes in blood pressure, cardiometabolic phenotype, plasma prorenin/renin, sPRR, and ANG II. After completing dietary protocols, tissues were collected from males to assess vascular reactivity and aortic reactive oxygen species (ROS). A cohort of male mice was used to determine the direct contribution of increased systemic sPRR by infusion. To investigate the role of ovarian hormones, ovariectomy (OVX) was performed at 32 wk in females fed either an NFD or HFD. Significant sex differences were found after 28 wk of HFD, where only males developed T2DM and increased plasma prorenin/renin, sPRR, and ANG II. T2DM in males was accompanied by nondipping hypertension, carotid artery stiffening, and aortic ROS. sPRR infusion in males induced vascular thickening instead of material stiffening caused by HFD-induced T2DM. While intact females were less prone to T2DM, OVX increased plasma prorenin/renin, sPRR, and systolic blood pressure. These data suggest that sPRR is a novel indicator of systemic RAAS activation and reflects the onset of vascular complications during T2DM regulated by sex. NEW & NOTEWORTHY High-fat diet (HFD) for 28 wk leads to type 2 diabetes mellitus (T2DM) phenotype, concomitant with increased plasma soluble prorenin receptor (sPRR), nondipping blood pressure, and vascular stiffness in male mice. HFD-fed female mice exhibiting a preserved cardiometabolic phenotype until ovariectomy revealed increased plasma sPRR and blood pressure. Plasma sPRR may indicate the status of systemic renin-angiotensin-aldosterone system (RAAS) activation and the onset of vascular complications during T2DM in a sex-dependent manner. [ABSTRACT FROM AUTHOR]

Background: Hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) community-acquired pneumonia (CAP) and associated comorbidities are at increased risk of cardiovascular complications. The magnitude of effect of cardiovascular complications and the role of prior comorbidities on clinical outcomes are not well defined.Research Question: What is the impact of cardiovascular complications on mortality in hospitalized patients with SARS-CoV-2 CAP? What is the impact of co-morbidities and other risk factors on the risk of developing cardiovascular complications and mortality in these patients?Study Design and Methods: This cohort study included 1,645 hospitalized patients with SARS-CoV-2 CAP. Cardiovascular complications were evaluated. The clinical course during hospitalization was described using a multistate model with 4 states: hospitalized with no cardiovascular complications, hospitalized with cardiovascular complications, discharged alive, and dead. Cox proportional hazards regression was used to analyze the impact of prior comorbid conditions on transitions between these states. Hazard ratios (HRs) and 95% confidence intervals (CIs) were reported.Results: Cardiovascular complications occurred in 18% of patients hospitalized with SARS-CoV-2 CAP. The mortality rate in this group was 45% versus 13% in patients without cardiovascular complications. Males (HR: 1.32, 95% CI: 1.03-1.68), older adults (HR: 1.34, 95% CI: 1.03-1.75), patients with congestive heart failure (HR: 1.59, 95% CI: 1.18-2.15), coronary artery disease (HR: 1.34, 95% CI: 1.00-1.79), atrial fibrillation (HR: 1.43, 95% CI: 1.06-1.95), direct admissions to the ICU (HR: 1.77, 95% CI: 1.36-2.32) and PaO2/FiO2 less than 200 (HR: 1.46, 95% CI: 1.11-1.92) were more likely to develop cardiovascular complications after hospitalization for SARS-CoV-2 CAP; however, these factors are not associated with increased risk of death after a cardiovascular complication. [ABSTRACT FROM AUTHOR]

Type 2 diabetes is a chronic disease requiring comprehensive pharmacological and non-pharmacological interventions to slow its progression and prevent or delay its micro- and macrovascular complications. Oxidative stress contributes to the development and progression of type 2 diabetes as well as to the development of its complications through several mechanisms. Therefore, therapeutic targeting of oxidative stress could aid in managing this disease and its complications. In our study, we have collected information on the most frequently used antidiabetic drugs (metformin, glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors) in the EU and the USA based on their antioxidant effects. Based on our results, we can conclude that the antioxidant effects of the investigated antidiabetics may contribute significantly to the management of the disease and its complications and may open new therapeutic perspectives in their prevention. • Diabetes increases the amount of reactive oxygen species and decreases the antioxidant defenses. • Oxidative stress contributes to β-cell dysfunction and insulin resistance. • Oxidative stress plays a significant role in the cardiovascular complications associated with diabetes. • Metformin, GLP-1 agonists, and SGLT2 inhibitors have antioxidant and protective effects on the cardiovascular system. [ABSTRACT FROM AUTHOR]

Background and Objectives: Since publishing successful clinical trial results of mRNA coronavirus disease 2019 (COVID‐19) vaccines in December 2020, multiple reports have arisen about cardiovascular complications following the mRNA vaccination. This study provides an in‐depth account of various cardiovascular adverse events reported after the mRNA vaccines' first or second dose including pericarditis/myopericarditis, myocarditis, hypotension, hypertension, arrhythmia, cardiogenic shock, stroke, myocardial infarction/STEMI, intracranial hemorrhage, thrombosis (deep vein thrombosis, cerebral venous thrombosis, arterial or venous thrombotic events, portal vein thrombosis, coronary thrombosis, microvascular small bowel thrombosis), and pulmonary embolism. Methods: A systematic review of original studies reporting confirmed cardiovascular manifestations post‐mRNA COVID‐19 vaccination was performed. Following the PRISMA guidelines, electronic databases (PubMed, PMC NCBI, and Cochrane Library) were searched until January 2022. Baseline characteristics of patients and disease outcomes were extracted from relevant studies. Results: A total of 81 articles analyzed confirmed cardiovascular complications post‐COVID‐19 mRNA vaccines in 17,636 individuals and reported 284 deaths with any mRNA vaccine. Of 17,636 cardiovascular events with any mRNA vaccine, 17,192 were observed with the BNT162b2 (Pfizer−BioNTech) vaccine, 444 events with mRNA‐1273 (Moderna). Thrombosis was frequently reported with any mRNA vaccine (n = 13,936), followed by stroke (n = 758), myocarditis (n = 511), myocardial infarction (n = 377), pulmonary embolism (n = 301), and arrhythmia (n = 254). Stratifying the results by vaccine type showed that thrombosis (80.8%) was common in the BNT162b2 cohort, while stroke (39.9%) was common with mRNA‐1273 for any dose. The time between the vaccination dosage and the first symptom onset averaged 5.6 and 4.8 days with the mRNA‐1273 vaccine and BNT162b2, respectively. The mRNA‐1273 cohort reported 56 deaths compared to the 228 with BNT162b2, while the rest were discharged or transferred to the ICU. Conclusion: Available literature includes more studies with the BNT162b2 vaccine than mRNA‐1273. Future studies must report mortality and adverse cardiovascular events by vaccine types. [ABSTRACT FROM AUTHOR]

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a type of human coronavirus that resulted in the 2019 coronavirus disease (COVID-19). Although it was generally categorized as a respiratory disease, its involvement in cardiovascular complications was identified from the onset. Elevated cardiac troponin levels (a myocardial injury marker) and echocardiograms, which showed the anomalous performance of the patients' hearts, were noted in the early case reports obtained from Wuhan, China. A couple of mechanisms have been proposed to explain COVID-19-induced cardiovascular complications, with systemic inflammation being the major focus recently. Chest pain and palpitations are among the prevalent symptoms in moderate to severe COVID-19-recovering patients. Cardiac damage potentially occurs due to multifactorial factors, which include cytokine-induced inflammation, direct cardiotoxicity, and disseminated intravascular coagulation (DIC), among others. The cardiovascular manifestations include cardiac arrhythmia, cardiogenic shock, venous thromboembolism, and elevated cardiac biomarkers. Both the long- and short-term effects of these cardiovascular complications remain puzzling to researchers, as substantial evidence is yet to be gathered to reach a consensus on the severity of COVID-19 in the heart. The treatment considerations currently include antiarrhythmic management, ACEI or ARB use, anticoagulation, hemodynamic support, and immunosuppression. This review aimed to outline the pathogenesis of the various cardiac complications due to COVID-19 as well as the available treatment modalities of COVID-19 infection. Both the mechanisms and the treatments have been succinctly explained in a proper manner to ensure understanding. [ABSTRACT FROM AUTHOR]